Physicians' human papillomavirus vaccine recommendations in the context of permissive guidelines for male patients: A national study

Teri L. Malo, Anna R. Giuliano, Jessica A. Kahn, Gregory D. Zimet, Ji Hyun Lee, Xiuhua Zhao, Susan T. Vadaparampil

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Little is known about physicians' human papillomavirus (HPV) vaccine recommendations for males while the Advisory Committee on Immunization Practices' (ACIP) permissive guidelines for male vaccination were in effect. The purpose of this study was to examine and explore factors associated with U.S. physicians' HPV vaccine recommendations to early (ages 11-12), middle (13-17), and late adolescent/young adult (18-26) males. Methods: Nationally representative samples of family physicians and pediatricians were selected in 2011 (n = 1,219). Physicians reported the frequency with which they recommended HPV vaccine to male patients ["always" (>75% of the time) vs. other] for each age group. Statistically significant predictors of vaccine recommendation were identified using multivariable logistic regression. Results: The prevalence of physicians reporting they "always" recommended HPV vaccination for males was 10.8% for ages 11 to 12, 12.9% for ages 13 to 17, and 13.2% for ages 18 to 26. Pediatrician specialty and selfreported early adoption of new vaccines were significantly associated with recommendation for all patient age groups. In addition, physician race and patient payment method were associated with physician recommendations to patients ages 11 to 12, and patient race was associated with recommendations to ages 13 to 17 and 18 to 26. Conclusions: Less than 15% of physicians surveyed reported "always" recommending HPV vaccine to male patients following national guidelines for permissive vaccination. Vaccine financing may have affected physicians' vaccine recommendations. Impact: If these recommendation practices continue following the ACIP's routine recommendation for males in October 2011, then interventions designed to increase recommendations should target family physicians and possibly use early adopters to encourage support of HPV vaccination guidelines.

Original languageEnglish (US)
Pages (from-to)2126-2135
Number of pages10
JournalCancer Epidemiology Biomarkers and Prevention
Volume23
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Papillomavirus Vaccines
Guidelines
Physicians
Vaccination
Vaccines
Family Physicians
Age Groups
Advisory Committees
Practice Guidelines
Young Adult
Immunization
Logistic Models

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Physicians' human papillomavirus vaccine recommendations in the context of permissive guidelines for male patients : A national study. / Malo, Teri L.; Giuliano, Anna R.; Kahn, Jessica A.; Zimet, Gregory D.; Lee, Ji Hyun; Zhao, Xiuhua; Vadaparampil, Susan T.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 23, No. 10, 01.10.2014, p. 2126-2135.

Research output: Contribution to journalArticle

Malo, Teri L. ; Giuliano, Anna R. ; Kahn, Jessica A. ; Zimet, Gregory D. ; Lee, Ji Hyun ; Zhao, Xiuhua ; Vadaparampil, Susan T. / Physicians' human papillomavirus vaccine recommendations in the context of permissive guidelines for male patients : A national study. In: Cancer Epidemiology Biomarkers and Prevention. 2014 ; Vol. 23, No. 10. pp. 2126-2135.
@article{53a8969d6a1f4dc1b52671f0be15387b,
title = "Physicians' human papillomavirus vaccine recommendations in the context of permissive guidelines for male patients: A national study",
abstract = "Background: Little is known about physicians' human papillomavirus (HPV) vaccine recommendations for males while the Advisory Committee on Immunization Practices' (ACIP) permissive guidelines for male vaccination were in effect. The purpose of this study was to examine and explore factors associated with U.S. physicians' HPV vaccine recommendations to early (ages 11-12), middle (13-17), and late adolescent/young adult (18-26) males. Methods: Nationally representative samples of family physicians and pediatricians were selected in 2011 (n = 1,219). Physicians reported the frequency with which they recommended HPV vaccine to male patients [{"}always{"} (>75{\%} of the time) vs. other] for each age group. Statistically significant predictors of vaccine recommendation were identified using multivariable logistic regression. Results: The prevalence of physicians reporting they {"}always{"} recommended HPV vaccination for males was 10.8{\%} for ages 11 to 12, 12.9{\%} for ages 13 to 17, and 13.2{\%} for ages 18 to 26. Pediatrician specialty and selfreported early adoption of new vaccines were significantly associated with recommendation for all patient age groups. In addition, physician race and patient payment method were associated with physician recommendations to patients ages 11 to 12, and patient race was associated with recommendations to ages 13 to 17 and 18 to 26. Conclusions: Less than 15{\%} of physicians surveyed reported {"}always{"} recommending HPV vaccine to male patients following national guidelines for permissive vaccination. Vaccine financing may have affected physicians' vaccine recommendations. Impact: If these recommendation practices continue following the ACIP's routine recommendation for males in October 2011, then interventions designed to increase recommendations should target family physicians and possibly use early adopters to encourage support of HPV vaccination guidelines.",
author = "Malo, {Teri L.} and Giuliano, {Anna R.} and Kahn, {Jessica A.} and Zimet, {Gregory D.} and Lee, {Ji Hyun} and Xiuhua Zhao and Vadaparampil, {Susan T.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1158/1055-9965.EPI-14-0344",
language = "English (US)",
volume = "23",
pages = "2126--2135",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Physicians' human papillomavirus vaccine recommendations in the context of permissive guidelines for male patients

T2 - A national study

AU - Malo, Teri L.

AU - Giuliano, Anna R.

AU - Kahn, Jessica A.

AU - Zimet, Gregory D.

AU - Lee, Ji Hyun

AU - Zhao, Xiuhua

AU - Vadaparampil, Susan T.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Background: Little is known about physicians' human papillomavirus (HPV) vaccine recommendations for males while the Advisory Committee on Immunization Practices' (ACIP) permissive guidelines for male vaccination were in effect. The purpose of this study was to examine and explore factors associated with U.S. physicians' HPV vaccine recommendations to early (ages 11-12), middle (13-17), and late adolescent/young adult (18-26) males. Methods: Nationally representative samples of family physicians and pediatricians were selected in 2011 (n = 1,219). Physicians reported the frequency with which they recommended HPV vaccine to male patients ["always" (>75% of the time) vs. other] for each age group. Statistically significant predictors of vaccine recommendation were identified using multivariable logistic regression. Results: The prevalence of physicians reporting they "always" recommended HPV vaccination for males was 10.8% for ages 11 to 12, 12.9% for ages 13 to 17, and 13.2% for ages 18 to 26. Pediatrician specialty and selfreported early adoption of new vaccines were significantly associated with recommendation for all patient age groups. In addition, physician race and patient payment method were associated with physician recommendations to patients ages 11 to 12, and patient race was associated with recommendations to ages 13 to 17 and 18 to 26. Conclusions: Less than 15% of physicians surveyed reported "always" recommending HPV vaccine to male patients following national guidelines for permissive vaccination. Vaccine financing may have affected physicians' vaccine recommendations. Impact: If these recommendation practices continue following the ACIP's routine recommendation for males in October 2011, then interventions designed to increase recommendations should target family physicians and possibly use early adopters to encourage support of HPV vaccination guidelines.

AB - Background: Little is known about physicians' human papillomavirus (HPV) vaccine recommendations for males while the Advisory Committee on Immunization Practices' (ACIP) permissive guidelines for male vaccination were in effect. The purpose of this study was to examine and explore factors associated with U.S. physicians' HPV vaccine recommendations to early (ages 11-12), middle (13-17), and late adolescent/young adult (18-26) males. Methods: Nationally representative samples of family physicians and pediatricians were selected in 2011 (n = 1,219). Physicians reported the frequency with which they recommended HPV vaccine to male patients ["always" (>75% of the time) vs. other] for each age group. Statistically significant predictors of vaccine recommendation were identified using multivariable logistic regression. Results: The prevalence of physicians reporting they "always" recommended HPV vaccination for males was 10.8% for ages 11 to 12, 12.9% for ages 13 to 17, and 13.2% for ages 18 to 26. Pediatrician specialty and selfreported early adoption of new vaccines were significantly associated with recommendation for all patient age groups. In addition, physician race and patient payment method were associated with physician recommendations to patients ages 11 to 12, and patient race was associated with recommendations to ages 13 to 17 and 18 to 26. Conclusions: Less than 15% of physicians surveyed reported "always" recommending HPV vaccine to male patients following national guidelines for permissive vaccination. Vaccine financing may have affected physicians' vaccine recommendations. Impact: If these recommendation practices continue following the ACIP's routine recommendation for males in October 2011, then interventions designed to increase recommendations should target family physicians and possibly use early adopters to encourage support of HPV vaccination guidelines.

UR - http://www.scopus.com/inward/record.url?scp=84907487122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907487122&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-14-0344

DO - 10.1158/1055-9965.EPI-14-0344

M3 - Article

C2 - 25028456

AN - SCOPUS:84907487122

VL - 23

SP - 2126

EP - 2135

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 10

ER -